Advisory Board and Editors Epigenetics
Albert Cheng
Albert Cheng obtained his BSc in Biochemistry and MPhil in Biology from Hong Kong University of Science and Technology in 2005 and 2007, respectively. He studied neurotrophin signaling and C. elegans developmental genetics. He then pursued his PhD in Computational & Systems Biology at MIT in the labs of Profs Christopher Burge and Rudolf Jaenisch and worked on various topics on epigenetics, gene regulation and alternative splicing in stem cells, reprogramming, cancer metastasis, erythropoiesis and differentiation. Cheng and colleagues identified H3K27ac as a signature for active enhancers. He analyzed alternative splicing in epithetlial-mesenchymal transition, cancer metastasis as well as erythropoiesis and identified splicing factors regulating these processes. He constructed CRISPR-on, an artificial RNA-guided activator based on CRISPR/Cas. After graduating in 2014, he joined the Jackson Laboratory at Bar Harbor, ME, as one of the first JAX scholars where he continued to work on understanding and improving the CRISPR/Cas technology. In July 2015, he started his own lab as an assistant professor at the Jackson Laboratory for Genomic Medicine campus at Farmington, CT.
Krystyna Dąbrowska
Affiliation: Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland (Bacteriophage Laboratory).Position: professor.
Current field of interest: non-bactericidal effects of phages in mammals; i.e. phage molecular biology tools for studies of phage impact on immunological system and other physiological aspects in mammals.
Mohammed Kuddus
Dr. Mohammed Kuddus is working as a Professor and Chairman of Biochemistry Department at University of Hail, Saudi Arabia. His main research area includes Molecular biology, Industrial enzymes, Extremophiles and Extremozymes, Microbial biotechnology, Food biotechnology, Waste utilization, Value added products, Bioremediation, Biopolymers and Bioplastics. He has published more than 75 research articles in reputed international journals along with 8 books and 22 book chapters; and presented more than 40 abstracts in national/international conferences/symposia. He has been serving as an Editor / Editorial Board Member and Reviewer of various international reputed journals. He has been awarded Young Scientist Projects from the Department of Science and Technology, India and International Foundation for Science, Sweden.
Thimios A Mitsiadis
Professor of Oral Biology in the Medical Faculty at the University of Zurich, Switzerland since 2006. Research in the fields of stem cells, genetics, molecular and experimental biology related to orofacial developmental and regeneration processes.
DDS degree from the Dental Faculty of the Kapodistrion University of Athens (Greece), Master degree for Immunology, Genetics and Differentiation, and PhD in Developmental Biology from the University of Lyon (France). Postdoctoral studies at the University of Helsinki (Finland), Karolinksa Nobel Institute (Stockholm, Sweden) and Yale University (USA). Previously Professor at the Mediterranean University (Marseilles, France), Visiting Professor at the Ecole Normale Superieure of Lyon (France), Clinical Senior Lecturer at King's College London (UK), Visiting Professor at the Polytechnic University of Marche (Ancona, Italy), Visiting Professor at the Second University of Napoli (Napoli, Italy). Chief-Editor of the “Frontiers of Craniofacial Biology and Dental Research”, Associate Editor of “Stem Cell Research”, Scientific Editor of “European Cells & Materials”, and part of the editorial board in additional 8 scientific journals. More than 110 original articles in journals such as “Journal of Cell Biology”, “Development”, “Developmental Biology”, “Nature Genetics”, “Science Signaling”, “Scientific Reports”, “Frontiers in Physiology” and more than 200 keynote and invited lectures.
Corey Nislow
Corey Nislow's laboratory develops and uses cutting edge tools to address this central question: how can we understand the biological commonalities in all of the life sciences; from embryonic development, to the spread of infectious diseases to better ways to treat cancer. Each of these disciplines can be explained in the context of competition, interaction and evolution. His lab studies the interface between genes and the environment using parallel genome-wide screens, high throughput cell-based assays and next generation sequencing. Most recently, he and his scientific partner, Dr. Guri Giaever, are exploring how laboratory experiments can co-opt evolutionary processes to understand drug action. He enjoys teaching all aspects of biotechnology, genomics and drug discovery. He got his PhD from the University of Colorado, worked at several Biotechnology companies and was at Stanford and University of Toronto before joining UBC in 2013. He has published 161 papers and run 19 marathons.
Olorunseun O Ogunwobi
Dr. Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, and a PhD in molecular biology from the University of East Anglia, Norwich, United Kingdom. He was the Founding Director of the Hunter College Center for Cancer Health Disparities Research. He is now the Barnett Rosenberg Professor of Biochemistry and Molecular Biology and Chairperson in the Department of Biochemistry and Molecular Biology at Michigan State University. In addition, he will serve as Co-Director of the forthcoming Center for Cancer Health Equity Research (CCHER) at Michigan State University. He is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with racial disparities, and on approaches to leverage non-coding RNA biology for potential clinical applications in cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi was a Founding Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705 from the National Cancer Institute. An author of 74 peer-reviewed journal articles and 3 book chapters, Dr. Ogunwobi has been issued 5 US patents for biotechnology inventions with potential clinical applications in cancer. He is the recipient of the 2022 Hunter College Presidential Award for Excellence in Scholarship or Creative Activity, and selected as a Jefferson Science Fellow by the National Academies of Sciences, Engineering, and Medicine, and as a Fellow of the Academy of Medicine Specialties of Nigeria. He is Co-Founder of UTR Therapeutics, Inc (winner of the 2023 XSeed Award from Deerfield), and NucleoBio, Inc.
Xavier Pochon
Team Leader, Molecular Surveillance, Biosecurity Group, Cawthron Institute, New Zealand.
Associate Professor, Institute of Marine Science, University of Auckland, New Zealand.
My research at the Cawthron Institute is highly applied and consist of developing multi-trophic molecular tools for environmental monitoring of marine industries (e.g. aquaculture farms, marine biosecurity in ports and marinas, and deep-sea exploration).
At the University of Auckland, I combine 'real-world' and 'blue-sky' research applications, including; i) investigating functional underpinnings of Symbiodiniaceae in coral reef ecosystems, ii) characterizing microbiomes in aquaculture and natural settings, iii) measuring eDNA and eRNA decay rates in marine invertebrates and vertebrates, iv) studying preferential settlement of marine invasive species associated with marine plastic debris, and v) exploring the diversity and dynamics of open-ocean plankton communities in the Pacific and beyond.